Clinical trials located in

Ratingen

Ratingen city is located in Germany. Currently, 9 clinical trials are being conducted in this city.

Ratingen, nestled in North Rhine-Westphalia, Germany, boasts a rich history dating back to the 9th century. This city, once a crucial hub in the textile industry, has evolved into a modern locale while preserving its historical charm. Landmarks like the medieval water castle Haus zum Haus and the 13th-century St. Peter and Paul Church highlight Ratingen’s architectural heritage. The city is also surrounded by the scenic beauty of the Rhine-Ruhr region, offering a blend of cultural and natural attractions. Ratingen’s transformation from a medieval town to a contemporary city reflects its dynamic history and cultural significance.

  • CT-EU-00116201

    Study of the new oral drug LY3871801 for rheumatoid arthritis

    The aim of this study is to test a new drug called LY3871801 for people suffering from moderate to severe rheumatoid arthritis. The main goal is to see if this new drug can help reduce disease activity and improve symptoms better than a placebo. In the first part of the study, doctors will check how much the Disease Activity Score changes after 12 weeks of taking LY3871801 or a placebo. Then, in the second part, they will look at what percentage of patients experience significant improvement, defined as achieving an ACR50 response, which means reducing symptoms of rheumatoid arthritis by 50% or more. Both the real drug and the placebo will be taken by mouth.

    • placebo
    • LY3871801
  • A study comparing upadacitinib versus adalimumab in the treatment of rheumatoid arthritis

    This clinical trial is studying a new medication called upadacitinib for treating moderate to severe rheumatoid arthritis. Rheumatoid arthritis is a chronic condition that causes pain, stiffness, swelling, and loss of joint function. The study will compare upadacitinib, which is taken as an oral tablet once daily, to adalimumab (brand name Humira), which is an injection given under the skin every other week.

    The main goal is to see how effective upadacitinib is at reducing disease activity compared to adalimumab. The study will measure the percentage of participants who achieve a certain level of low disease activity based on a score called the DAS28-CRP, which looks at tender and swollen joints, overall disease activity, and inflammation levels.

    This is a double-blind study, meaning neither the participants nor the study doctors will know which treatment each participant is receiving. Participants will attend regular visits at a hospital or clinic for medical assessments, checking for side effects, and completing questionnaires. There may be a higher treatment burden compared to standard care. The study is designed to assess the safety and effectiveness of upadacitinib compared to adalimumab in treating moderate to severe rheumatoid arthritis.

    • Adalimumab
    • Upadacitinib
  • Evaluating SAR441566 in Adults with Moderate-to-Severe Rheumatoid Arthritis

    This clinical trial is designed to explore the effectiveness and safety of a new medication called SAR441566 in adults who are dealing with moderate-to-severe rheumatoid arthritis (RA). If you’re an adult who hasn’t found relief from RA with methotrexate alone and haven’t tried biologic or targeted synthetic disease-modifying anti-rheumatic drugs yet, this study might be of interest to you.

    The study is set up as a double-blind, placebo-controlled experiment, which means neither you nor the study team will know if you’re receiving the actual medication or a placebo. This is a key part of ensuring the results are unbiased. You’ll be randomly placed into one of five groups, with some receiving SAR441566 and others a placebo, all alongside your regular methotrexate treatment.

    The trial will last for about 149 days, including a 6-week period before the treatment starts to confirm your eligibility, a 12-week treatment phase, and a 2-week follow-up period after treatment ends to monitor your safety. Throughout the study, you’ll visit the study center 8 times.

    One of the main goals of this study is to see if participants show a significant improvement in their RA symptoms, specifically looking for a 20% improvement in the American College of Rheumatology (ACR) score by week 12. This score measures various aspects of RA, including joint tenderness and swelling, pain levels, and overall physical function.

    By participating, you’ll be contributing to research that could lead to new treatment options for RA, potentially offering relief to many who are searching for more effective therapies.

    • SAR441566
    • placebo
  • Secukinumab study for maintaining remission in axial spondyloarthritis

    The aim of this study is to see if a drug called Secukinumab can maintain remission in people with non-radiographic axial spondyloarthritis (a type of spondylitis). Remission means that there is no or very little disease in the body. To determine whether a person is in remission, we use a special scoring system that looks at various symptoms of arthritis and a blood test for a protein associated with inflammation (C-reactive protein, or CRP). The aim of the study is to see whether people who stop taking Secukinumab will experience an exacerbation (worsening of the disease) and how long it takes for this to happen. The study will last just over two years.

    • Secukinumab
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Testing new treatment with other drugs for advanced breast cancer

    This study is exploring a new treatment for women with advanced breast cancer. It focuses on patients who have hormone receptor-positive, HER2-negative breast cancer and a specific genetic change (ESR1 mutation). About 300 women will participate. The study compares a new drug, AZD9833 in combination with a group of drugs called CDK4/6 inhibitors (palbociclib, abemaciclib, or ribociclib) with standard treatments (anastrozole or letrozole) in combination with CDK4/6 inhibitor. The aim is to see if AZD9833 works better than standard treatments in stopping cancer from growing.

    • Camizestrant
    • Luteinizing hormone-releasing hormone (LHRH) agonist
    • Abemaciclib
    • Palbociclib
    • Ribociclib
    • Anastrozole
    • Letrozole
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Germany:

.